Article

Panoptx launches new logo, new models, new technology

Panoptx has launched a new logo with a stylized number 7, tied to a new brand (7EYE), along with a renewed emphasis on the treatment of dysfunctional tear syndrome (DTS) and servicing independent dispensaries that care for patients with DTS symptoms.

Pleasanton, CA-Panoptx has launched a new logo with a stylized number 7, tied to a new brand (7EYE), along with a renewed emphasis on the treatment of dysfunctional tear syndrome (DTS) and servicing independent dispensaries that care for patients with DTS symptoms.

Explaining the rationale behind the new name, Bob Hall, Panoptx president and chief executive officer, said, "We wanted a name with instant recognition, a logo that would stand out, a domain name that people could spell, a name with youthful energy and attitude. We found that combination with the 7EYE logo and brand.

The first Panoptx frames bearing the 7EYE logo are being introduced as 7EYE by Panoptx Limited Edition III series to the motorcycle market, where Panoptx first became a hit among Harley-Davidson riders.

"The introduction of 7EYE is the beginning of a new platform for product development," Hall continued.

"We are creating a solid foundation for brand expansion and sales growth, and with new styles and new technology in the pipeline, 7EYE will fuel that growth."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.